company background image
BSLN logo

Basilea Pharmaceutica SWX:BSLN Stock Report

Last Price

CHF 45.40

Market Cap

CHF 550.3m

7D

1.5%

1Y

17.3%

Updated

13 Oct, 2024

Data

Company Financials +

Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 550.3m

BSLN Stock Overview

A commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.

BSLN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Basilea Pharmaceutica AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Basilea Pharmaceutica
Historical stock prices
Current Share PriceCHF 45.40
52 Week HighCHF 47.95
52 Week LowCHF 32.00
Beta0.70
11 Month Change-0.55%
3 Month Change14.36%
1 Year Change17.31%
33 Year Change5.39%
5 Year Change12.88%
Change since IPO-55.05%

Recent News & Updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01
Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24
Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18
If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Shareholder Returns

BSLNCH BiotechsCH Market
7D1.5%4.9%1.0%
1Y17.3%91.6%10.4%

Return vs Industry: BSLN underperformed the Swiss Biotechs industry which returned 91.6% over the past year.

Return vs Market: BSLN exceeded the Swiss Market which returned 10.4% over the past year.

Price Volatility

Is BSLN's price volatile compared to industry and market?
BSLN volatility
BSLN Average Weekly Movement4.8%
Biotechs Industry Average Movement7.6%
Market Average Movement3.5%
10% most volatile stocks in CH Market6.9%
10% least volatile stocks in CH Market1.5%

Stable Share Price: BSLN's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: BSLN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
2000156David Veitchwww.basilea.com

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections.

Basilea Pharmaceutica AG Fundamentals Summary

How do Basilea Pharmaceutica's earnings and revenue compare to its market cap?
BSLN fundamental statistics
Market capCHF 550.30m
Earnings (TTM)-CHF 652.00k
Revenue (TTM)CHF 149.02m

3.7x

P/S Ratio

-844.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BSLN income statement (TTM)
RevenueCHF 149.02m
Cost of RevenueCHF 124.90m
Gross ProfitCHF 24.12m
Other ExpensesCHF 24.78m
Earnings-CHF 652.00k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.054
Gross Margin16.19%
Net Profit Margin-0.44%
Debt/Equity Ratio570.0%

How did BSLN perform over the long term?

See historical performance and comparison